AARD: Aardvark Therapeutics Corp Analyst Consensus Forecast

The price trajectory of Aardvark Therapeutics Inc (AARD) reflects current market dynamics, where the key indicator stands at 4.57. The business focuses on developing non-invasive obesity treatments, advancing the ARD-101 appetite suppressant. Aardvark Therapeutics Inc integrates green synthesis into its production while adhering to bioethics. High margins are sustained by orphan drug status and total loyalty from patients with rare genetic pathologies.

AARD: Aardvark Therapeutics Inc. Analyst Consensus Forecast 02/14/2025 - 11/14/2026

Analytical breakdowns for Aardvark Therapeutics Inc (AARD)

- stock value and consensus price forecast:

Stock Price Aardvark Therapeutics|AARD - Analyst Consensus Forecast

- market capitalization information:

Market Capitalization Aardvark Therapeutics|AARD - Total Company Value

- balance sheet equity data:

Accounting Value of a Share Aardvark Therapeutics|AARD - Book Capitalization|Capitalization to Book Value Ratio aardvarktherapeutics.com|AARD - Aggregate Company Assets

- issuer credit burden and liquidity indicators:

Aggregate Debt to Equity Aardvark Therapeutics Inc|AARD - Long-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital Aardvark Therapeutics Inc|AARD - Company Aggregate Debts|Debts to Book Capitalization Aardvark Therapeutics|AARD - Company Long-Term Debt|Company Short-Term Loans and Borrowings Aardvark Therapeutics|Quick Liquidity Indicator aardvarktherapeutics.com

- earnings and valuation multiples information:

AARD - Net Profit|Projected Future Earnings Aardvark Therapeutics Inc|AARD - Price to Earnings Ratio|Future Price to Earnings Multiple Aardvark Pharma|AARD - Price/Earnings to Growth Ratio|Enterprise Value to EBITDA Ratio Aardvark Pharma|AARD - Operating profit EBITDA|Net earnings per one share for the last twelve months Aardvark Therapeutics|AARD - Net earnings per share for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months aardvarktherapeutics.com|AARD - Earnings growth in current year|Earnings growth forecast for next year Aardvark Therapeutics Inc

- issuer revenue and sales details:

AARD - Revenue and Sales Volume|Company Projected Revenue Aardvark Therapeutics Inc.|AARD - Price-to-Revenue Ratio|Market Cap to Future Revenue Ratio Aardvark Therapeutics

General company analysis:AARD Aardvark Therapeutics Inc.

For Aardvark Therapeutics Inc (AARD), a developer of innovative anti-obesity drugs, the market consensus on the stock price reflects a cumulative assessment of its patent portfolio's potential. This indicator aggregates independent analyst price targets, measuring the gap between the current quote and the asset's fundamental value, allowing investors to promptly identify whether shares are overvalued or undervalued based on the curve's dynamics.

Competitors of Aardvark Therapeutics Inc